Kidney injury occuring in liver failure is a historical scenario imbued w/in the parlance of medicine for centuries. In this article, I try to discuss HRS— its current concepts & challenges.
Thank you @Nephro_Sparks@DearbhlaKelly4 for helping me write this article!
#NephJC Consensus
From GEMRITUX, MENTOR, STARMEN, RI-CYCLO & now MAJESTY- the signal remains consistent:
✅ Anti-CD20 therapy works
✅ Remissions are durable
✅ Relapses are lower than CNIs
Check out anti-CD20 trials in pMN @CristinaDeReins👇
#NephJC#TenPostNephJC#NephTwitter
#TenPostNephJC#NephTwitter#NephJC
1/10
How often do we miss non-diabetic kidney disease (NDKD)?
🚩NDKD are 1) active urine sediment, 2) sudden worsening RFT, 3) absence of retinopathy 4) systemic symptoms like rash
@Tiff_Caza
https://t.co/0H9Rydx60J
Hypertension control remains stubbornly low in underserved communities. IMPACTS‑BP asks whether a team‑based, multi‑component approach can meaningfully improve blood pressure control and adherence in low‑income patients
🎨#VisualAbstract by @DrAkshayaJ
https://t.co/liZjXaThwl
Tigris: 15k screened, 157 enrolled, and a result that depends on how much you trust the prior #NephJC
💡Signal? Yes
🤔Confidence? Not really
✍️#NephJCshort by @CristinaDeReins
🪓Reviwed by @hswapnil and @brian_rifkin
https://t.co/BNNnUiXdqD
1/10
#NephJC#TenPostNephJC.
#NephTwitter
In 2026 💊 FDA approved sparsentan for FSGS, an endothelin A/angiotensin II receptor inhibitor.
Next up in the pipeline…transient receptor potential cation channel 6 (TRPC6) inhibitor (BI 764198) 🚰
Article 👇
https://t.co/DxVeKVlF0x
Blessings abound! The Division received various awards during the recent convention:
1. One of the Most Outstanding Fellowship Training Institution in Adult Nephrology
2. 100% passing recent Board exams
3. One of the Best performing institution in test construction
#TatakPGH
Hydralazine, a 1950s drug still used at the edges of modern care
Cheap. Available.
Signal of benefit… shadowed by decades of immune toxicity signals
58 min to #TenPostNephJC#NephJC
https://t.co/IShXIbNyle
Managing glomerular disease in tropical regions require a specialized lens. Join #GlomConPH on April 22, 2026, for a high-impact workshop designed for physicians to master the nuances of tropical nephrology—from biopsy interpretation to navigating the latest KDIGO updates.
0/10
Hey NephJC faithful, we are shaking it up.
Given the 📉 attendance at live chats we’re changing to a summary 🧵& ❓ to answer, at your convenience.
Still tag us #NephJC to get the discussion going!
PS If we hear enough comments, we might bring chats back!😉
Hey #NephTwitter#MedTwitter
📣If you were planning on coming to the #NephJC chat on hyponatremia 4/7/26 at 9 pm...relax, we're trying something new (and it will be here on Twitter too, not just BlueSky)!
https://t.co/TAbRWdgr7k
The IgAN Nephropathy curriculum provides a comprehensive review of the pathogenesis, treatment, and prediction of disease progression to help clinicians in their work.
Access the new curriculum, supported by Otsuka: https://t.co/KPQtAz86g0
#ISNWCN second HIT1 trial
Semaglutide Improves Kidney Outcomes Regardless Of SGLT2i Use In People With Chronic Kidney Disease And Type 2 Diabetes: Post-hoc Analysis The Remodel Trial, by David Cherney
#ISNWCN
First simultaneous publication comes from Hiddo Heerspink and ASSIST trial ✨
Phase II randomized crossover in IgAN on RASi+SGLT2i. Atrasentan 0.75 mg reduced 24-h UPCR vs placebo. ETA blockade adds antiproteinuric effect on top of optimized therapy
2/ @brian_rifkin 's recap highlighted our progress and future plans, but what stays with me is this: #nephjc never stops adapting. We keep learning, improving, and reaching for a better version of ourselves 🌟